Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan
Nutrients · 2023
DOI: 10.3390/nu15020445 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, 2023. Verfasst von Arastu Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Extracellular Matrix Regeneration, Department of Health Sciences and Technology, Institute of Translational Medicine, ETH Zürich, 8603 …. Hauptthemen laut MEDLINE: NAD, Sirtuin 1. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 205 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation.
Abstract (Originalsprache)
Disrupted biological function, manifesting through the hallmarks of aging, poses one of the largest threats to healthspan and risk of disease development, such as metabolic disorders, cardiovascular ailments, and neurodegeneration. In recent years, numerous geroprotectors, senolytics, and other nutraceuticals have emerged as potential disruptors of aging and may be viable interventions in the immediate state of human longevity science. In this review, we focus on the decrease in nicotinamide adenine dinucleotide (NAD+) with age and the supplementation of NAD+ precursors, such as nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR), in combination with other geroprotective compounds, to restore NAD+ levels present in youth. Furthermore, these geroprotectors may enhance the efficacy of NMN supplementation while concurrently providing their own numerous health benefits. By analyzing the prevention of NAD+ degradation through the inhibition of CD38 or supporting protective downstream agents of SIRT1, we provide a potential framework of the CD38/NAD+/SIRT1 axis through which geroprotectors may enhance the efficacy of NAD+ precursor supplementation and reduce the risk of age-related diseases, thereby potentiating healthspan in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Extracellular Matrix Regeneration, Department of Health Sciences and Technology, Institute of Translational Medicine, ETH Zürich, 8603 Schwerzenbach, Switzerland.
- AVEA Life AG, Bahnhofplatz, 6300 Zug, Switzerland.
- Department of Dermatology, University Hospital of Basel, 4031 Basel, Switzerland.
- Robert Larner, MD College of Medicine at the University of Vermont, Burlington, VT 05405, USA.
- Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
- Maximon AG, Bahnhofplatz, 6300 Zug, Switzerland.
ORCID-Profile: Collin Y Ewald
Förderung
- Swiss National Science Foundation
Zitieren
APA
Sharma, A., Chabloz, S., Lapides, R. A., Roider, E., & Ewald, C. Y. (2023). Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan. Nutrients. https://doi.org/10.3390/nu15020445
Vancouver
Sharma A, Chabloz S, Lapides RA, Roider E, Ewald CY. Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan. Nutrients. 2023. doi:10.3390/nu15020445
BibTeX
@article{Sharma2023,
author = {Sharma, Arastu and Chabloz, Sophie and Lapides, Rebecca A and Roider, Elisabeth and Ewald, Collin Y},
title = {Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15020445}
}
EUVIMED